Atlas Advisors Australia product partner Stoic Asset Management becomes largest co-investor in Hotel

August 19, 2021 1 min read

Atlas Advisors Australia product partner Stoic Asset Management becomes largest co-investor in Hotel

Atlas Advisors Australia product partner Stoic Asset Management becomes largest co-investor in Hotel Accommodation Fund.

Atlas Advisors Australia’s product partner Stoic Asset Management has become the largest co-investor in Elanor Investors Group’s (ASX: ENN) newly established Hotel Accommodation Fund significantly growing its holdings in key property-backed domestic tourism assets across Australia.

Stoic Asset Management is a unique outcome-driven investment management that designs fit for purpose investment products.

It is also the sole co-investor in Elanor’s Wildlife Park Fund and the majority investor in Elanor’s Burke Street Real Estate and Healthcare Real Estate funds.

The $346 million Hotel Accommodation Fund is focused on the luxury and regional hotel sectors and currently holds 14 high-quality hotels.

The fund’s strategy is to grow the portfolio to more than $500 million and a potential listing on the Australian Securities Exchange.

Ms Bao said Stoic Asset Management, just months into operation, was already generating significant gains for Atlas Advisors Australia investors.

“Stoic Asset Management takes a unique design house approach to uniquely tailor products for specific client situations,” she said.

“To do this we partner with the best and brightest talent in the market including Australia’s leading investment managers in property, bonds, small caps or venture capital, providing strong returns with rigorous institutional risk management.”



Also in News

Workzone West leads the way in WA
Workzone West leads the way in WA

March 03, 2022 2 min read

THE Workzone West building at 202 Pier Street in the Perth CBD is now the first carbon neutral 6 Star NABERS Energy rated commercial building in Western Australia.
ENA Respiratory and the COPD Foundation Partner to Develop Pan-Antiviral Nasal Spray
ENA Respiratory and the COPD Foundation Partner to Develop Pan-Antiviral Nasal Spray

February 24, 2022 3 min read

INNA-051 is being developed to stimulate innate immunity and reduce the incidence and severity of respiratory viral infections, such as COVID-19, rhinovirus, or influenza in populations at-risk of complications that include individuals with COPD
Perennial, Arbel double down on SME lender Lumi
Perennial, Arbel double down on SME lender Lumi

February 21, 2022 2 min read

Only two months since it closed a $20 million round, SME lender Lumi has raised another $10 million, thanks to the growth of its loan book drastically exceeding its forecasts.